UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2019

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____________ to ____________

Commission file number: 000-27781

UNITED HEALTH PRODUCTS, INC.

(Exact name of Company as specified in its charter)

Nevada	84-1517723
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

10624 S. Eastern Ave., Suite A209 Henderson, NV	89052
(Address of Company's principal executive offices)	(Zip Code)

(877) 358-3444

(Company's telephone number, including area code)

None

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class:	Trading Symbol(s)	Name of each exchange on which registered:
Common Stock	UEEC	OTC Pink

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by checkmark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Section 232.405) of this Chapter) during the 12 preceding months (or such shorter period that the registrant was required to submit such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	¨	Accelerated filer	¨
Non-accelerated filer	x	Smaller reporting company	x
		Emerging growth company	¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

The number of shares issued of the Registrant's Common Stock, as of October 31, 2019 was 176,588,907 issued and outstanding.

UNITED HEALTH PRODUCTS, INC.

FORM 10-Q QUARTERLY REPORT

TABLE OF CONTENTS

		PAGE
PART I. FINANCIAL INFORMATION
Item 1.	Financial Statements (Unaudited)	3
	Condensed Balance Sheets as of September 30, 2019 and December 31, 2018 (unaudited)		3
	Condensed Statements of Operations for the Three and Nine Months Ended September 30, 2019 and September 30, 2018 (unaudited)		4
	Condensed Statement of Stockholders’ Deficiency for the Three and Nine Months Ended September 30, 2019 and September 30, 2018 (unaudited)		5
	Condensed Statements of Cash Flows for the Nine Months Ended September 30, 2019 and September 30, 2018 (unaudited)		7
	Notes to Condensed Financial Statements (unaudited)		8
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations		14
Item 3.	Quantitative and Qualitative Disclosures		18
Item 4.	Controls and Procedures		18
PART II. OTHER INFORMATION
Item 1.	Legal Proceedings		19
Item 1A.	Risk Factors		19
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds		19
Item 3.	Defaults Upon Senior Securities		19
Item 4.	Mine Safety Disclosures		19
Item 5.	Other Information		19
Item 6.	Exhibits and Reports on Form 8-K		20
SIGNATURES			21

2

UNITED HEALTH PRODUCTS, INC.

Condensed Balance Sheets

(Unaudited)

	September 30,			December 31,
	2019			2018
ASSETS
Current Assets
Cash and Cash Equivalents	$	88,219		$	31,273
Accounts Receivable		36,019			11,010
Inventory		109,627			83,694
Total current assets		233,865			125,977
TOTAL ASSETS	$	233,865		$	125,977
Current Liabilities
Accounts payable and accrued expenses	$	306,895		$	243,713
Liability for unissued shares		201,843			201,843
Accrued liabilities - related parties		17,251			25,000
Notes payable – related parties		-			8,121
Total current liabilities		525,989			478,677
Commitments and Contingencies
Stockholders' Deficiency
Common Stock - $.001 par value, 300,000,000 Shares
Authorized, 176,588,907 and 185,943,138 shares issued at September 30, 2019 and December 31, 2018, respectively and 176,588,907 and 171,793,138 shares outstanding at September 30, 2019 and December 31, 2018, respectively		176,589			185,943
Additional Paid-In Capital		23,403,837			19,198,343
Accumulated Deficit		(23,872,550	)		(19,736,986	)
Total Stockholders' Deficiency		(292,124	)		(352,700	)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIENCY	$	233,865		$	125,977

See notes to unaudited condensed financial statements.

3

UNITED HEALTH PRODUCTS, INC.

Condensed Statements of Operations

(Unaudited)

	For the Three Months Ended September 30,						For the Nine Months Ended September 30,
	2019			2018			2019			2018
Revenues	$	-		$	9,048		$	25,009		$	40,826
Cost of goods sold		-			3,480			9,887			14,147
Gross profit		-			5,568			15,122			26,679
Operating Costs and Expenses
Selling, general and administrative expenses		294,847			403,359			3,609,708			1,700,442
Research and development		141,820			-			384,088			-
Total Operating Expenses		436,667			403,359			3,993,796			1,700,442
Loss from Operations		(436,667	)		(397,791	)		(3,978,674	)		(1,673,763	)
Other Income (Expenses)
Interest Expense		-			-			(156,890	)		-
Other Income		-			-			-			3,886
Loss on debt settlement		-			-			-			(3,632,500	)
Total other income (expenses)		-			-			(156,890	)		(3,628,614	)
Net Loss	$	(436,667	)	$	(397,791	)	$	(4,135,564	)		(5,302,377	)
Net Loss per common share:
Basic and diluted	$	(0.00	)	$	(0.00	)	$	(0.02	)		(0.03	)
Weighted average number of shares outstanding		176,588,907			170,672,664			174,693,659			169,553,562

See notes to unaudited condensed financial statements.

4

UNITED HEALTH PRODUCTS, INC

Condensed Statement of Stockholders' Deficiency

Three and Nine Months Ended September 30, 2018

(Unaudited)

					Additional
	Common Stock				Paid-in			Accumulated
	Shares		Amount		Capital			Deficit			Total
Balance at December 31, 2017		164,969,663	$	164,969	$	13,304,617		$	(13,730,851	)	$	(261,265	)
Issuance of shares for notes payable and accrued interest		3,500,000		3,500		3,811,500			-			3,815,000
Issuance of common stock for services		50,000		50		54,450			-			54,500
Sale of common stock		440,725		441		275,660			-			276,101
Shares issued for liability of unissued shares		62,500		63		4,937			-			5,000
Shares held in escrow		14,150,000		14,150		(14,150	)		-			-
Net Loss		-		-		-			(3,990,041	)		(3,990,041	)
Balance at March 31, 2018		183,172,888	$	183,173	$	17,437,014		$	(17,720,892	)	$	(100,705	)
Issuance of common stock for services		800,000		800		619,200			-			620,000
Sale of common stock		698,697		699		481,401			-			482,100
Shares issued for liability of unissued shares		137,059		137		91,863			-			92,000
Net Loss		-		-		-			(914,545	)		(914,545	)
Balance at June 30, 2018		184,808,644	$	184,809	$	18,629,478		$	(18,635,437	)	$	178,850
Sale of common stock		14,494		14		9,986			-			10,000
Net Loss		-		-		-			(397,791	)		(397,791	)
Balance at September 30, 2018		184,823,138	$	184,823	$	18,639,464		$	(19,033,228	)	$	(208,941	)

See notes to unaudited condensed financial statements

5

UNITED HEALTH PRODUCTS, INC

Condensed Statement of Stockholders' Deficiency

Three and Nine Months Ended September 30, 2019

(Unaudited)

	Common Stock						Additional Paid-in		Accumulated
	Shares			Amount			Capital		Deficit			Total
Balance at December 31, 2018		185,943,138		$	185,943		$	19,198,343	$	(19,736,986	)	$	(352,700	)
Vesting of shares held in escrow		-			-			2,343,500		-			2,343,500
Issuance of common stock for services		400,000			400			379,600		-			380,000
Sale of common stock		150,000			150			74,850		-			75,000
Cancellation of escrow shares		(12,000,000	)		(12,000	)		12,000		-			-
Net Loss		-			-			-		(2,985,897	)		(2,985,897	)
Balance at March 31, 2019		174,493,138		$	174,493		$	22,008,293	$	(22,722,883	)	$	(540,097	)
Sale of common stock		1,685,769			1,686			1,034,064		-			1,035,750
Issuance of shares for notes payable and accrued liabilities – related party		410,000			410			204,590		-			205,000
Beneficial conversion feature		-			-			156,890		-			156,890
Net Loss		-			-			-		(713,000	)		(713,000	)
Balance at June 30, 2019		176,588,907		$	176,589		$	23,403,837	$	(23,435,883	)	$	144,543
Net Loss		-			-			-		(436,667	)		(436,667	)
Balance at September 30, 2019		176,588,907		$	176,589		$	23,403,837	$	(23,872,550	)	$	(292,124	)

See notes to unaudited condensed financial statements.

6

UNITED HEALTH PRODUCTS, INC.

Condensed Statements of Cash Flows

(Unaudited)

	For the Nine Months Ended September 30,
	2019			2018
Cash Flows from Operating Activities:
Net (Loss)	$	(4,135,564	)	$	(5,302,377	)
Adjustments to Reconcile net (loss) to Net Cash Used In Operating Activities:
Stock based compensation		2,723,500			674,500
Loss on settlement of debt		-			3,632,500
Bad debt expense		-			100,000
Expenses paid by officer		-			30,000
Amortization of debt discount		156,890			-
Changes in assets and liabilities:
Accounts Receivable		(25,009	)		(8,429	)
Inventory		(25,933	)		2,701
Prepaid and other current assets		-			12,114
Accounts payable and accrued expenses		63,182			(41,763	)
Accrued liabilities – related party		(2,870	)		-
Net Cash Used in Operating Activities		(1,245,804	)		(900,754	)
Cash Flows from Investing Activities:		-			-
Cash Flows from Financing Activities:
Proceeds from related party notes payable		292,000			15,000
Repayments to related party		(100,000	)		(143,500	)
Repayment on notes payable		-			(10,000	)
Proceeds from sale of common stock		1,110,750			980,200
Cash flow provided by financing activities		1,302,750			841,700
Increase in Cash and Cash Equivalents		56,946			(59,054	)
Cash and Cash Equivalents – Beginning of period		31,273			189,942
CASH AND CASH EQUIVALENTS – END OF PERIOD	$	88,219		$	130,888
Supplemental cash flow information:
Cash paid for interest	$	-		$	-
Cash paid for income taxes	$	-		$	-
Non-cash Investing & Financing Activities:
Shares issued for debt and accrued interest	$	-		$	182,500
Shares issued related to liability for unissued shares	$	-		$	97,000
Shares issued and held in escrow	$	-		$	14,150
Share issued for notes payable and accrued liabilities – related party	$	205,000		$	-
Cancellation of shares	$	12,000		$	-

See notes to unaudited condensed financial statements.

7

UNITED HEALTH PRODUCTS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

FOR THE QUARTERS ENDED SEPTEMBER 30, 2019 AND 2018

(unaudited)

Note 1. Organization and Basis of Preparation

United Health Products, Inc. ("United" or the "Company") is a product development and solutions company focusing its growth initiatives on the expanding wound-care industry and disposable medical supplies markets. The Company produces an innovative gauze product that absorbs exudate (fluids which have been discharged from blood vessels) by forming a gel-like substance upon contact.

Interim financial statements are prepared in accordance with GAAP for interim financial information and pursuant to the requirements for reporting on Form 10-Q and Article 8 of Regulation S-X, as appropriate. In the opinion of management, all adjustments, which are of a normal recurring nature, considered necessary for the fair presentation of financial statements for the interim period, have been included.

These interim condensed financial statements should be read in conjunction with the Company's audited financial statements and notes for the period ended December 31, 2018 filed with the Securities and Exchange Commission on Form 10-K filed on April 1, 2019. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted, as permitted by the SEC, although we believe the disclosures which are made are adequate to make the information presented not misleading.

Note 2. Significant Accounting Policies

Going Concern

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred recurring net losses and operations have not provided cash flows. Additionally, the Company does not currently have sufficient revenue producing operations to cover its operating expenses and meet its current obligations. In view of these matters, there is substantial doubt about the Company's ability to continue as a going concern. The Company intends on financing its future development activities and its working capital needs largely from the sale of public equity securities with some additional funding from other traditional financing sources, including term notes until such time that funds provided by operations are sufficient to fund working capital requirements. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

The Chief Executive Officer has agreed to advance funds or make payments of the Company's obligations at his discretion. There is no written agreement to continue this support.

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires the Company's management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reported period. Changes in the economic environment, financial markets, as well as in the healthcare industry, and any other parameters used in determining these estimates, could cause actual results to differ.

8

Trade Accounts Receivable and Concentration Risk

We record accounts receivable at the invoiced amount and we do not charge interest. We review the accounts receivable by amounts due from customers which are past due, to identify specific customers with known disputes or collectability issues. In determining the amount of the reserve, we make judgments about the creditworthiness of significant customers based on ongoing credit evaluations. We will also maintain a sales allowance to reserve for potential credits issued to customers. We will determine the amount of the reserve based on historical credits issued.

There was no provision for doubtful accounts recorded at September 30, 2019 and December 31, 2018. The Company recorded $0 and $0 in bad debt expense for the three- and nine- month periods ended September 30, 2019, respectively. The Company recorded $100,000 and $100,000 in bad debt expense for the three- and nine-month periods ended September 30, 2018, respectively.

For the nine months ended September 30, 2019, one customer made up of 100% of the Company’s net revenue and three customers made up 94% of the Company’s outstanding accounts receivable balance.

For the nine months ended September 30, 2018, three customers accounted for 48%, 29% and 12% of the Company’s net revenue, respectively. 

For the year ended December 31, 2018, three customers made up 98.9% of the Company’s outstanding accounts receivable balance.

Inventory

Inventory is valued at the lower of cost or market using the first-in, first-out (FIFO) method. Inventory on the balance sheet consists of raw materials purchased by the Company and finished goods.

	September 30, 2019		December 31, 2018
Raw materials	$	81,941	$	46,121
Finished goods		27,686		37,573
	$	109,627	$	83,694

During the nine months ended September 30, 2019 and 2018, the Company determined $0 and $0, respectively, of inventory should be impaired and written-off to cost of goods sold.

Stock Based Compensation

The Company issues restricted stock to consultants and employees for various services. Costs for these transactions are measured at the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. The value of the common stock for non-employees is measured at the date at which a firm commitment for performance by the counterparty to earn the equity instruments is reached and expense is recognized during the term at which the counterparty's performance is earned or at the date the shares are considered non-forfeitable. The Company recognized consulting expenses and a corresponding increase to additional paid-in-capital related to stock issued for services. 

9

Per Share Information

Basic earnings per share are calculated using the weighted average number of common shares outstanding for the period presented. Diluted earnings per share is computed using the weighted-average number of common shares and, if dilutive, potential common shares outstanding during the period. Potential common shares consist of the shares of common stock held in escrow. The dilutive effect of potential common shares is not reflected in diluted earnings per share because the Company incurred a net loss for the three and nine months ended September 30, 2019 and 2018 and the effect of including these potential common shares in the net loss per share calculations would be anti-dilutive.

The total potential common shares as of September 30, 2019 and 2018, include 50,100,000 of restricted stock units and 14,150,000 of common stock held in escrow, respectively.

New Accounting Pronouncements, Recently Adopted Accounting Pronouncements

Leases

 In February 2016, the FASB issued Accounting Standards Update (ASU) No. ASU 2016-02, Leases, which amends existing lease accounting guidance, including the requirement to recognize most lease arrangements on the balance sheet. The adoption of this standard will result in the Company recognizing a right-of-use asset representing its rights to use the underlying asset for the lease term with an offsetting lease liability. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, with early adoption permitted. The Company has determined there is no impact to the financial statements as the Company does not have any lease agreements.

The Company considers all new pronouncements and management has determined that there have been no other recently adopted or issued accounting standards that had or will have a material impact on its financial statements. 

Note 3. Related Party Transactions

As of September 30, 2019 and December 31, 2018, notes payable to related parties totaled $0 and $8,121, respectively. These amounts are owed to Doug Beplate, our Chief Executive Officer. During the nine months ended September 30, 2019, Mr. Beplate advanced the Company $292,000 and the Company made repayments to Mr. Beplate totaling $100,000.

On April 22, 2019, the Company agreed to issue to Mr. Beplate convertible demand loans representing all outstanding cash loans made by Mr. Beplate to the Company. For any outstanding loans made on or before April 15, 2019, the loans are convertible at $0.50 per share and for all loans subsequent to April 15, 2019, the notes are convertible at $0.65 per share, in each case at the sole discretion of Mr. Beplate. The Company’s stock price on April 22, 2019 was $0.90 which resulted in a beneficial conversion feature of $156,890 which was recorded to interest expense.

During the nine months ended September 30, 2019, Mr. Beplate converted $205,000 of notes payable and accrued liabilities at a conversion price of $0.50 into 410,000 shares of common stock. There is $0 remaining as unamortized debt discount.

During the year ended December 31, 2018, Mr. Beplate gave a personal vehicle to an employee of the Company valued at $30,000 in lieu of the Company paying travel expenses and consulting expenses. During 2018, the Company repaid a net amount of $305,207 of the outstanding notes payable balance from proceeds of private placements. These loans were for operating expenses of the Company, were due on demand and had no interest rate.

Per Mr. Beplate’s services agreement, he receives monthly compensation of $15,000 per month. During the year ended December 31, 2018, he received his entire salary of $180,000 and $61,500 of previously accrued compensation was paid, leaving a balance of $25,000. During the nine months ended September 30, 2019, $22,130 of compensation was accrued and $4,879 was converted into stock as mentioned above, leaving a balance of $17,251.

10

In March 2019, the Company granted Mr. Beplate 33,000,000 Restricted Stock Units (RSU’s) which vest and are issuable upon the achievement of certain conditions described in Note 4. These RSU’s were included as part of the Company’s grant of an aggregate of 50,100,000 RSUs to various officers, directors and consultants which all vest on substantially the same terms. The RSUs granted to Mr. Beplate replaced an executive compensation stock bonus package that was granted to Mr. Beplate in December 2018 which had provided that upon the sale of all or substantially all of the assets of the Company or other change in control or merger transaction in which the Company is involved, or in the event that no such transaction occurred by December 31, 2019, Mr. Beplate would have been entitled to receive a number of shares equal to 15% post issuance of the then outstanding shares of the Company's common stock on a fully diluted basis. The December 2018 executive compensation stock bonus package had, in turn, replaced a previously issued 5% stock bonus granted to Mr. Beplate that would have been issuable in the event of a sale of the Company’s assets or change in control or merger transaction, per his services agreement. See “Note 4” regarding the granting of the RSUs.

During the nine months ended September 30, 2019, the Company issued 100,000 shares of common stock to each of two directors for services rendered. The shares had a fair market value of $190,000.

Note 4. Issuances of Securities

Share issuances 2018

During the nine months ended September 30, 2018, the Company issued an aggregate of 19,853,475 shares of common stock. The Company issued 850,000 shares of common stock with a total fair market value of $674,500 for services, 1,283,728 shares of common stock were sold for total proceeds of $980,200, $125,000 of the proceeds received were for 181,159 shares of common stock not yet issued and recorded as liability for unissued shares, 69,747 shares of common stock were issued related to $10,000 of previously recorded liability for unissued shares during 2017 and 14,150,000 shares of common stock with a fair market value of $15,423,500 were issued to officers and various consultants for services to be provided related to a change of control of the Company and placed in escrow. The shares were to be released from escrow upon the change of control of the Company. Management was unable to determine when a change of control will occur and $0 was expensed as of September 30, 2018. The Company also issued 3,500,000 shares of common stock to convert $172,500 of notes payable and $10,000 of accrued interest. The shares were valued at their fair market value of $1.09 which resulted in a loss on debt settlement of $3,632,500.

Share issuances 2019

During the nine months ended September 30, 2019, 1,435,769 shares of common stock were sold to non-affiliated investors in a private placement for total cash proceeds of $910,750, 400,000 shares of common stock were sold to securities counsel for total cash proceeds of $200,000, 200,000 shares of common stock were issued to securities counsel for services rendered with a fair value of $190,000, 100,000 shares of common stock were issued to each of two directors for services rendered with a fair value of $190,000 and 410,000 shares of common stock were issued to the Company’s CEO for conversion of notes payable and accrued liabilities totaling $205,000. 

During the nine months ended September 30, 2019, the following events occurred with respect to the aforementioned 14,150,000 shares held in escrow: 

During the period ended September 30, 2019, the Company issued (i)1,600,000 shares to Nate Knight who is the Chief Financial Officer of the Company, 500,000 shares to the office administrator, who is a person affiliated with the Company’s CEO and 50,000 shares to a Technical Product Supervisor, who is the son of the office administrator which had been held in escrow and became vested by the Board of Directors for services provided. These shares had a fair market value of $1.09 per share at the date of issuance and $2,343,500 has been expensed during the nine-month period ended September 30, 2019.

The Company canceled 12,000,000 shares of the aforementioned 14,150,000 shares issued (which were escrowed and not considered outstanding) in the first quarter of 2019 to various officers, directors and consultants.

11

Restricted stock units

The Board approved Restricted Stock Unit Agreements (“RSU Agreements”) with certain of its officers, directors and consultants representing an aggregate of 50,100,000 shares of common stock to be issued and delivered to such persons upon the earlier of (i) a change in control of the Company by a cash tender offer, merger, acquisition or otherwise or (ii) the Company achieving quarterly gross revenue that, when annualized, represents gross annual revenues of at least $20,000,000 by December 31, 2019, or (iii) the commencement of an action or event by a third party without the Board’s approval to effect, or seek to effect, a change in control of the Company or change in the Company’s management.

			Weighted
			Average
			Grant
	Number of		Date Fair
	Units		Value
Total awards outstanding at December 31, 2018		-	$	-
Units granted		50,100,000	$	0.94
Units Exercised/Released		-	$	-
Units Cancelled/Forfeited		-	$	-
Total awards outstanding at September 30, 2019		50,100,000	$	0.94

Management is unable to determine when a change of control will occur and as of September 30, 2019, there was $47,094,000 of unrecognized compensation cost related to unvested restricted stock unit awards.

Note 5. Litigation

During 2017, a Complaint was filed with the United States District Court, Southern District of New York by Steven Safran as Plaintiff against the Company and Douglas Beplate, its CEO, as Defendant. This court case was transferred to the United States District Court in Las Vegas, Nevada. Mr. Safran is seeking damages and monies allegedly owed pursuant to an employment agreement and allegedly unpaid loans of $245,824 provided to Defendants. The Company has denied Plaintiff’s allegations and intends to vigorously defend said lawsuit. The parties have held various depositions and the Company has a motion to dismiss which is pending with the court. No accrual has been recorded related to this litigation.

In July 2015, the Company entered into a consulting agreement retaining the services of Maxim Group LLC. An amended agreement was executed in January 2018. A total of 4 million shares of common stock were issued to Maxim in exchange for its obligation to perform certain advisory and other services. In the fourth quarter of 2018, the Company notified Maxim of its intent to file for arbitration pursuant to the consulting agreement. Maxim, without providing a similar notice to the Company, immediately filed a complaint with FINRA seeking release of a restrictive legend from a Company stock certificate in the amount of 500,000 shares. The Company filed an affirmative defense that the required notice of arbitration was not provided to the Company prior to filing. The Company also filed a counterclaim for breach of contract seeking restitution of the original 4 million shares issued to Maxim and the Company filed several counterclaims alleging material misrepresentations by Maxim to various entities. The Company intends to vigorously defend Maxim’s complaint and to seek to obtain relief pursuant to its counterclaims. Currently, the Company and Maxim have rescheduled arbitration dates with FINRA which will be held in the first quarter of 2020.

Philip Forman, who served in positions as Chairman, a director, Chief Executive Officer and Chief Medical Advisor at various time between 2011 and October 2015, has filed a lawsuit against the Company and our Chief Executive Officer, Douglas Beplate, in the United States District Court of the District of Nevada. The claimant is claiming, among other things, that: the June 25, 2015 Amendment to his November 10, 2014 Employment Agreement with the Company, which terminated the Employment Agreement on October 1, 2015, is not valid because of lack of consideration; that a July 22, 2015 Stock Purchase Agreement pursuant to which the claimant sold Company shares issued to him under the Amendment to a third a party is unenforceable (despite the fact that all payment for the shares under the Stock Purchase Agreement was made); that the plaintiff’s 2014 Employment Agreement is enforceable and that he is entitled to cash and stock compensation under that Employment Agreement (without giving regard to the Amendment); that if the Amendment is enforceable, he is entitled to the shares issued under the Amendment (without mention that those shares were sold to a third party under the Stock Purchase Agreement described above); and that the Company and Mr. Beplate defrauded the plaintiff relating to the foregoing. The plaintiff is seeking declaratory judgment regarding the parties’ relative rights under the Employment Agreement, the Amendment and the Stock Purchase Agreement; money damages of no less than $2,795,000; and punitive damages of $8,280,000. The Company believes that it has meritorious defenses to the matters claimed as well as counterclaims against the claimant. We filed a motion to dismiss the plaintiff’s claims which is pending before the court.

12

FSR Inc. commenced a lawsuit in 2018 against Korsair Holdings A.G. in the U.S. District Court for the Southern District of New York, seeking among other claims for relief, rescission of the transfer of 3,050,000 shares of United Health Products that FSR sold to Korsair in 2011. Third-Party Plaintiff, JEC Consulting Associates, LLC as Liquidator of LeadDog Capital L.P., Intervenor (“Intervenor”) in the above matter, filed a third-party complaint against United Health Products, and Douglas Beplate alleging among other things that the Company and Mr. Beplate refused to have the Rule 144 restrictive legend removed from the Korsair certificate held by JEC, and concomitantly fraudulently deprive JEC as Liquidator of LeadDog of the ability to sell the Shares in the open market, knowingly, intentionally and directly causing economic harm to LeadDog Capital L.P. Intervenor as Third Party Plaintiff further alleges that the Company and Mr. Beplate as Third-Party Defendants are not only monetarily liable to Third-Party Plaintiff for compensatory damages of $2,500,000 but should be made to pay exemplary damages in an amount determined by the Court, but not less than an equal amount - $2,500,000. Third-Party Plaintiff demands judgment for the above referenced amounts and for the Court to also declare that the 3,050,000 shares are free trading; that Third-Party Plaintiff’s rights to 2.5 million of the Shares are superior to the claims of Plaintiff FSR; that Plaintiff FSR has no claim to 2.5 million of the 3,050,000 Shares reflected by the Korsair certificate; that the Company and Mr. Beplate are to instruct its current transfer agent to remove the restrictive legend on the Korsair certificate for the Shares; and an order directing the Company and Mr. Beplate to instruct the Company’s transfer agent to exchange the Korsair certificate for new free-trading, unrestricted certificates. The Company believes that it had legal right to decline to instruct the transfer agent to remove the restrictive legend from the Korsair Shares where the ownership of the aforementioned shares have been in dispute and the Korsair shares have not been submitted for transfer to its transfer agent in proper form under the uniform commercial code.

In October 2019, the Company filed a defamation, trade libel and unlawful and deceptive practices lawsuit. See further details in Item 2.

Due to uncertainties inherent in litigation, we cannot predict the outcome of these legal proceedings.

Note 6. Liability for Unissued Shares

The Company has recognized a "Liability for unissued shares" for shares granted to employees and consultants along with shares purchased by investors, but unissued as of the balance sheet date. The granted shares are recorded at the fair market value of the shares to be issued at the grant date and a corresponding current liability is recorded for these unissued shares. The activity in this account and balances, classified as Liabilities for unissued shares, as of September 30, 2019 and December 31, 2018 was as follows:

	2019		2018
Balance, beginning	$	201,843	$	211,843
Issuance of shares in satisfaction of liability		-		10,000
Balance, ending	$	201,843	$	201,843

The total number of shares granted but unissued were 2,414,059 and 2,414,059, as of September 30, 2019 and December 31, 2018, respectively.

 Note 7. Subsequent Events

The Company has evaluated events subsequent to September 30, 2019, through the date whereupon the financial statements were issued and has determined that there are no material events that need to be disclosed.

13

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.

You should read the following discussion and analysis of our financial condition and results of operations together with our condensed financial statements and related notes appearing elsewhere in this quarterly report on Form 10-Q. This discussion and analysis contain forward-looking statements that involve risks, uncertainties and assumptions. The actual results may differ materially from those anticipated in these forward-looking statements as a result of certain factors, including, but not limited to, those set forth under 'Risk Factors' in our annual report on Form 10-K for the fiscal year ended December 31, 2018, filed with SEC on April 1, 2019.

Recent Developments

The following developments in the Company’s business have occurred during 2019:

· In August 2019, the Company successfully completed the surgeries for its Human Trial study “Efficacy and Safety of HemoStyp as an Adjunct for Management of Secondary Hemostasis in the Operative Setting” which finalized human trial enrollment. The Company is compiling and presenting all study data and human surgical results to an independent firm that will certify all data and finalize the Company’s Class III PMA submission for FDA approval.

· In August 2019, the Company filed a patent application covering methods of forming and using a hemostatic material, and more specifically, methods of forming and using a hemostatic hydrocolloid that is formed into a gel, foam or spray used to control bleeding and oozing from a variety of wounds. The approval of the new patent would allow for the HemoStyp hydrocolloid to act as a conduit to transfer other properties associated with the treatment of wounds within the hydrocolloid. This would enable HemoStyp to be bundled as a suite of multiple products for surgical and wound care applications. We cannot assure that our patent application will be granted.

· Furthermore, in August 2019, the Company received the pathology results of a preclinical animal study to assess the effect of HemoStyp on bone tissue. The Company conducted the animal study to evaluate the suitability of HemoStyp in contact with bone in the chronic swine model, and to validate HemoStyp for this application. This study and indication are independent of the current PMA application and will potentially allow UHP to access new and significant market opportunities. The study results determined that there was no adverse pH effect on the bone and surrounding tissue, which UHP believes demonstrate the potential for safe application of HemoStyp in human orthopedic procedures.

· Additionally, in August 2019, the final patient had completed their follow up study visit in the Company’s HemoStyp Human Clinical Trial. This trial was conducted on 236 Western Institutional Review Board approved and consented patients. Comparative hemostatic product testing was conducted on Level 1 and Level 2 bleeds on the Lewis bleeding scale during abdominal, cardiovascular, thoracic and vascular surgeries. The study is a randomized trial with safety and efficacy endpoints for FDA PMA Class III submission.

· In October 2019 the Company filed a defamation, trade libel and unlawful and deceptive practices lawsuit against White Diamond Research LLC, Adam Gefvert, Streetsweeper.org, Sonya Colberg and others in response to a stock manipulation scheme to injure UHP for illegitimate personal gain. The complaint alleges that in August 2019 the above defendants published false and defamatory statements about UHP in “short and distort” schemes to artificially drive down the market price of UHP’s common stock while at the same time having a short position in UHP’s stock, so they could obtain illicit profits on their short sale positions.

· Also, in October 2019 the Company received a final report by an independent reviewer of the result of its Human Trial study, confirming the non-inferiority and superiority of HemoStyp over Surgicel ORIGINAL, the market leader for hemostatic agents. This report will be integrated into the Company’s Class III PMA submission for FDA approval

14

Our HemoStyp Gauze Products

HemoStyp Hemostatic Gauze is an innovative collagen-like natural substance created from chemically treated cellulose. It is an effective hemostatic agent registered with the FDA to help control bleeding from open wounds and body cavities. The HemoStyp hemostatic material contains no chemical additives, thrombin or collagen, and is hypoallergenic. When the product comes in contact with blood it expands slightly and converts to an adhesive gel that subsequently dissolves into glucose and saline. Because of its purity and the fact that it simply degrades to non-toxic end products, HemoStyp does not cause significant delay in healing as do certain other hemostatic materials. Additional testing has shown HemoStyp to be 100% absorbable in 24 hours or less. Tests have also been conducted to demonstrate the effectiveness of HemoStyp in thoracic and abdominal procedures. The Company continues to test for the effectiveness and the IFU (Instructions for Use) for abdominal and thoracic procedures.

HemoStyp Hemostatic Gauze is a flexible cloth-like material that is applied by folding the gauze as needed to fit the size of the wound or incision, and then placing the gauze onto the bleeding tissue. In surgical situations, the product converts to a transparent gel with a neutral pH level that allows the surgeon to monitor the coagulation process and also avoids damage to the surrounding tissue. In first responder or other non-surgical situations, putting a bandage on top of the gauze is optional and, in many cases, unnecessary. Since EMS (Emergency Medical Services) work is pre-hospital, rinsing the gauze out with saline or water is not necessary, as a wound will be debrided and possibly reopened prior to suturing at the hospital.

Our hemostatic gauze product line includes various configurations which have been developed to address the specific needs of our market segments and our existing customers, including the U.S. military. Our HemoStyp gauze products are sold in different sizes for use in superficial trauma cases, as a dental gauze and as a nasal dressing, and in a range of formats for veterinary applications, among others uses. The Company's hemostatic gauze product line now includes the following products:

· Veterinary Market type Products;

· Dental gauze for oral surgery;

· Several formats of Trauma Gauze™ for battlefield trauma; Adhesive bandages for use by consumers on cuts and abrasions; and,

· Island dressings to support intravenous procedures such as kidney dialysis.

Existing and Potential Target Markets

Our technology is marketed as HemoStyp Gauze but is also available to customers with customized private labeling. We are customer driven. We distribute both nationally and internationally. We are servicing (or intend to service) our customers through distributors, sales representatives, industry-specialized telephone support, and the Internet. Our current and potential customer base for our HemoStyp includes, without limitation:

· Hospitals and Surgery Centers for all Internal Surgical usage, post FDA Class III approval

· Hospitals, Clinics and Physicians – For external trauma

· EMS, Fire Departments and Other First Responders

· Public Safety, Police Departments and Military

· Correctional Facilities

· Schools, Universities and Day Care Facilities

· Nursing Homes and Assisted Living Environments

· Home Care Providers

· Dental offices

· Sports Medicine Providers

· Veterinarians

· Municipalities and Government Agencies and

· Occupational and Industrial Healthcare Professionals Consumers

15

Plan of Operation

We believe that the Class III surgical markets, both domestic and international, represent the most attractive market for our products due to the limited competition from other Class III approved ORC (Oxidized Regenerated Cellulose) products and the resulting premium pricing for hemostatic agents that can meet the demanding requirements of the human surgical environment. In addition, our preliminary tests lead us to believe that the HemoStyp technology can compete successfully against established market participants and allow us to gain market share. Given this assessment, we have devoted considerable resources in 2018 and in 2019 to the date of this report to completing the FDA process.

Based on advice from the Company’s Medical Board our management believes, but cannot assure, that HemoStyp will receive Class III approval. In anticipation of that, our strategy is to devote resources and seek partnerships that allow us to penetrate this market along with the other markets to which the Company already has access. We are evaluating all potential paths for the Company, which could include commercial partnerships and licensing agreement with established market participants, in addition or as an alternative to raising the necessary capital to establish and grow our own marketing and distribution capabilities.

We believe that refocusing the Company to become a stronger, medical technology business with a patented technology will enhance the Company’s value and overall market strength and allows for revenue generation via organic growth. Nevertheless, we have engaged a financial advisor as described under “Recent Developments” to advise the Company on potential strategic alternatives including the possible sale of the Company and/or its intellectual assets. In the event that a transaction is not completed on terms satisfactory to the Company, we will require substantial additional capital to execute an organic business development strategy addressing all of our target markets.

Results of Operations

Three Months ended September 30, 2019 versus Three Months ended September 30, 2018

During the three months ended September 30, 2019 and 2018, the Company had $0 and $9,048 of revenues, respectively. The decrease in revenues is due to the Company not pursuing sales in the current quarter compared to achieving minimal revenues in the comparable quarter of the prior year.

Total operating expenses for the three months ended September 30, 2019 and 2018 were $436,667 and $403,359, respectively. The increase in operating expenses is due primarily to a decrease in bad debt expense of $100,000 offset by an increase in research and development expenses of $141,820. The increase in research and development expenses is due to higher expenditures on the ongoing process to obtain FDA Class III approval during the current period.

Our net loss for the three months ended September 30, 2019 and 2018 was $436,667 and $397,791, respectively. The increase in the net loss is due to reduced revenue and increased spending on research and development, offset by a decrease in bad debt expense as mentioned above.

Nine Months ended September 30, 2019 versus Nine Months ended September 30, 2018

During the nine months ended September 30, 2019 and 2018, the Company had $25,009 and $40,826 of revenues, respectively. The decrease in revenues is due to the reduced sales effort in 2019 as we focus on FDA Class III product approval.

Total operating expenses for the nine months ended September 30, 2019 and 2018 were $3,993,796 and $1,700,442, respectively. The increase in operating expenses is due primarily to an increase in consulting/professional fees and an increase in research and development expenses. The increase in consulting/professional fees include the issuance of 400,000 shares of our common stock for services valued at $380,000 and 2,150,000 shares of common stock valued at $2,343,500 vested during the nine months ended September 30, 2019 compared to the Company issuing 850,000 shares of common stock valued at $674,500 to various medical advisors during the nine month period ended September 30, 2018. The increase in research and development of $384,088 is due to higher expenses related to the FDA Class III approval process during the current period relative to the prior year.

16

Our net loss for the nine months ended September 30, 2019 was $4,135,564 as compared to net loss of $5,302,377 for the comparable period of the prior year. The decrease in the net loss is due to the Company having an increase in selling, general and administrative expenses of $1,909,266 as described above, an increase of $384,088 in research and development expenses along with an increase of $156,890 of interest expense related to amortization of debt discount related to beneficial conversion feature on notes payable – related party offset by a decrease of $3,632,500 in loss on settlement of debt.

Financial Condition, Liquidity and Capital Resources

As of September 30, 2019, the Company had working capital deficit of $292,124 and stockholders' deficit of $292,124. The Company has not as yet attained a level of operations which allows it to meet its current overhead and may not attain profitable operations within the next few business operating cycles, nor is there any assurance that such an operating level can ever be achieved. The report of our independent registered public accounting firm on our 2018 financial statements includes a reference to going concern which indicated substantial doubt about our ability to continue as a going concern. While the Company has in the past funded its initial operations with private placements, and loans from related parties, there can be no assurance that adequate financing will continue to be available to the Company and, if available, on terms that are favorable to the Company. Our ability to continue as a going concern is also dependent on many events outside of our direct control, including, among other things, our ability to achieve our business goals and objectives, as well as improvement in the economic climate.

Cash Flows

The Company's cash on hand at September 30, 2019 and December 31, 2018 was $88,219 and $31,273, respectively.

Net cash used in operating activities for the nine months ended September 30, 2019 was $1,245,804. The Company had a net loss of $4,135,564 offset by stock issued for services of $2,723,500 and amortization of debt discount of $156,890. The Company also had an increase in accounts receivable of $25,009, an increase in inventory of $25,933, an increase in accounts payable and accrued expenses of $63,182 and a decrease in accrued liabilities – related party of $2,870. Net cash provided by financing activities was $1,302,750. This was due to the Company receiving $1,110,750 in proceeds from the sale of stock and receiving net proceeds of $192,000 from a related party.

Net cash used in operating activities for the nine months ended September 30, 2018 was $900,754. The Company had net loss of $5,302,377 offset by stock issued for services of $674,500, bad debt expense of $100,000, expenses paid by an officer of $30,000 and loss on settlement of debt of $3,632,500. The Company also had an increase in accounts receivable of $8,429, a decrease in inventory of $2,701, a decrease in prepaids and other current assets of $12,114 and a decrease in accounts payable and accrued expenses of $41,763. Net cash provided by financing activities was $841,700. This was due to the Company receiving $980,200 in proceeds from the sale of stock and repaying a net amount of $128,500 in related party advances and $10,000 in notes payable.

Off-Balance Sheet Arrangements

As of September 30, 2019, we have no off-balance sheet arrangements.

Critical Accounting Policies

The preparation of financial statements and related disclosures in conformity with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and revenues and expenses during the periods reported. Actual results could materially differ from those estimates. We have identified the following items as critical accounting policies.

17

Revenue Recognition

The Company recognizes revenues in accordance with ASC 606 — Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the sale of its HemoStyp product by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied.

Stock Based Compensation

The Company issues restricted stock to consultants and employees for various services. Cost for these transactions are measured at the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. The value of the common stock for non-employees is measured at the date at which a firm commitment for performance by the counterparty to earn the equity instruments is reached and expense is recognized during the term at which the counterparty's performance is earned or at the date the shares are considered non-forfeitable. The Company recognized consulting expenses and a corresponding increase to additional paid-in-capital related to stock issued for services.

 Item 3. Quantitative and Qualitative Disclosures about Market Risk.

Not applicable 

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

The Company is in the process of implementing disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934 (the ''Exchange Act''), that are designed to ensure that information required to be disclosed in the Company's Exchange Act reports are recorded, processed, summarized, and reported within the time periods specified in rules and forms of the Securities and Exchange Commission, and that such information is accumulated and communicated to our Chief Executive Officer to allow timely decisions regarding required disclosure.

As of September 30, 2019, the Chief Executive Officer and Chief Financial Officer carried out an assessment of the effectiveness of the design and operation of our disclosure controls and procedure and concluded that the Company's disclosure controls and procedures were not effective as of September 30, 2019, because of the material weakness described below.

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company's annual or interim financial statements will not be prevented or detected on a timely basis.

The material weakness identified during management's assessment was the lack of sufficient resources with SEC, generally accepted accounting principles (GAAP) and tax accounting expertise. This control deficiency did not result in adjustments to the Company's interim financial statements. However, this control deficiency could result in a material misstatement of significant accounts or disclosures that would result in a material misstatement to the Company's interim or annual financial statements that would not be prevented or detected. Accordingly, management has determined that this control deficiency constitutes a material weakness.

The Chief Executive Officer and Chief Financial Officer performed additional accounting and financial analyses and other post-closing procedures including detailed validation work with regard to balance sheet account balances, additional analysis on income statement amounts and managerial review of all significant account balances and disclosures in the Quarterly Report on Form 10-Q, to ensure that the Company's Quarterly Report and the financial statements forming part thereof are in accordance with accounting principles generally accepted in the United States of America. Accordingly, management believes that the financial statements included in this Quarterly Report fairly present, in all material respects, the Company's financial condition, results of operations, and cash flows for the periods presented.

Changes in Internal Control over Financial Reporting

During the current quarterly period, there were no changes in our system of internal controls over financial reporting.

18

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

See “Note 5” in the Notes to Condensed Financial Statements.

Item 1A. Risk Factors

Not required for smaller reporting companies.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

(a) From January 1, 2019 through September 30, 2019, we had no sales or issuances of unregistered common stock, except we made sales or issuances of unregistered securities listed in the table below:

Date of Sale	Title of Security	Number Sold		Consideration Received and Description of Underwriting or Other Discounts to Market Price or Convertible Security, Afforded to Purchasers	Exemption from Registration Claimed	If Option, Warrant or Convertible Security, terms of exercise or conversion
Jan. – March 31, 2019	Common Stock		550,000	$75,000 in cash, $380,000 in services rendered, no commissions paid	Rule 506; Section 4(2)	Not applicable
April – September 30, 2019	Common Stock		2,095,769	$1,035,750 in cash, $205,000 conversion of notes payable and accrued liabilities	Rule 506; Section 4(2)	Convertible at $0.50/share

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

Not applicable.

 

19

Item 6. Exhibits

The following exhibits are filed with this report, or incorporated by reference as noted:

3(i)	Articles of Incorporation of the Company dated February 28, 1997. (1)
3(ii)	Amendment to Articles of Incorporation. (1)
3(iii)	By-laws of the Company. (2)
3(iv)	August 2015 Amendment to Articles of Incorporation. (3)
10.1	Services Agreement with Louis Schiliro (5)
10.2	Services Agreement – Nate Knight (4)

10.3	January 2015 Services Agreement with Douglas Beplate (6)
10.4	Restricted Stock Unit Agreement - Louis Schiliro( 8)
10.5	Restricted Stock Unit Agreement - Douglas Beplate(8)
21	Subsidiaries of the Registrant – none
31.1	Certification of Principal Executive Officer*
31.2	Certification of Principal Financial Officer*
32.1	Section 1350 Certificate by Principal Executive Officer*
32.2	Section 1350 Certificate by Principal Financial Officer*
99.1	2013 Employee Benefit and Consulting Services Compensation Plan (7)

101.SCH	Document, XBRL Taxonomy Extension (*)
101.CAL	Calculation Linkbase, XBRL Taxonomy Extension Definition (*)
101.DEF	Linkbase, XBRL Taxonomy Extension Labels (*)
101.LAB	Linkbase, XBRL Taxonomy Extension (*)
101.PRE	Presentation Linkbase (*)

 ___________ 

* Filed herewith.

(1)	Incorporated by reference to the Company's Form 10-Q for the quarter ended September 30, 2014.
(2)	Incorporated by reference to the Company's Form 10-K for the year ended December 31, 2005.
(3)	Incorporated by reference to Form 8-K dated August 7, 2015 – date of earliest event filed on August 10, 2015.
(4)	Incorporated by reference to Form 8-K dated November 23, 2014.
(5)	Incorporated by reference to the Company's Form 10-Q for the quarter ended June 30, 2018.
(6)	Incorporated by reference to the Form 8-K dated January 16, 2015.
(7)	Incorporated by reference to Form 10-Q for the quarter ended June 30, 2015.
(8)	Incorporated by reference to Form 10-K for the fiscal year ended December 31, 2018.

20

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this amended report to be signed on its behalf by the undersigned, thereunto duly authorized on November 1, 2019.

United Health Products, Inc.
By:	/s/ Douglas Beplate
	Douglas Beplate Principal Executive Officer

By:	/s/ Nate Knight
	Nate Knight
	Principal Financial Officer

  

21